Compare AbbVie Inc (ABBV) vs Gartner Inc (IT) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Gartner (IT) trades at $140.80, up 3.29% today, with a bearish technical signal but strong fundamental profitability. Recent earnings consistently beat estimates, with Q1 2026 EPS of $3.32 exceeding the $2.99 forecast. The company maintains robust margins, including a 68.99% gross profit margin and 11.44% net income margin, though 2025 net cash flow was negative $210.63 million. Analyst consensus price target is $158.00, suggesting potential upside from current levels.

The stock offers value with a P/E of 13.35 and P/S of 1.54, but high P/B of 142.72 and negative cash flow trends pose risks. Competitive pressures in IT consulting and reliance on enterprise spending are headwinds. Institutional sentiment is mixed with 27.78% buy ratings, indicating cautious optimism amid operational challenges.